Free Newsletter
FDA finds 'final link' in heparin case
For the first time, the FDA has conclusively tied patients' deaths to the contaminant found in Baxter's heparin blood thinner. Of 10 deaths reported from anaphylactic shock, three of them were traced to lot numbers of the drug that tested positive for oversulfated chondroitin sulfate. (The lot numbers of the other seven weren't known.) "We have what looks like cause and effect in some patients," Dr. Janet Woodcock, CDER chief, told the Chicago Tribune. "This is one of the final links in the chain."
As you know, Baxter recalled its heparin products in February after a spike in severe allergic reactions to the drug. The investigation led to suppliers in China, which, some officials said, may have contaminated raw heparin deliberately to save money. In the process, the probe raised questions about just how close an eye drugmakers keep on their foreign supply chains; Baxter admitted that it didn't know much about the ultimate source of the ingredient it bought from Scientific Protein Laboratories, which operated a plant in China. All told, FDA counted more than reports of more than 90 deaths and 1,000 adverse reactions to heparin.
- read the story in the Tribune
Related Articles:
Heparin mimic found in suspect samples
Heparin suspected in more deaths
Heparin supply chain full of loopholes
Baxter stops making multidose heparin
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: